Estrogen Receptor Agonist Market Trends

Growth Drivers

Growing Prevalence of Osteoporosis 18.3% of people worldwide were estimated to have osteoporosis in 2021. Hence, in order to treat osteoporosis, the demand is on a surge for estrogen receptor agonists. Raloxifene is the most common type of estrogen which is approved by FDA used for this treatment.
Rise in Women Suffering from PCOS Between 4% and 20% of women worldwide were believed to have PCOS in 2022. Further, PCOS have a huge adverse effect on female leading to irregular period and acne. Hence, polycystic ovary syndrome treatment on timely basis is necessary. Therefore, in order to control menstrual cycles in PCOS patients, oral contraceptives (OCs; with combined estrogen and progestin) are the most widely used form of medication.
Surge in the Application of Estrogen in Asthma There has been growing research on the use of estrogen receptor agonist in the treatment of asthma. Beyond the reproductive system, estrogen plays a variety of tasks in both males and females, including controlling inflammation, intracellular calcium levels, and cell proliferation and differentiation. One of the characteristics of asthma is the infiltration of inflammatory cells such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils into the airways, particularly eosinophilic infiltration. Hence, it is poised that the estrogen receptor agonist would be used. Hence, further, the investment in research activities on this topic is anticipated to rise in order to prove the conclusion.

Challenges

High Cost of Treatment
Lack of Processionals who are Skilled in this Field – The use of estrogen receptor agonists is a new form of treatment on which still research is going on for its use to treat different diseases. Hence, not a large number of people are aware of this treatment. Also, since it is not popular enough there is a lack of professionals, especially in rural regions. Hence, this factor is projected to hinder the estrogen receptor agonist market growth.
Adverse Effect of Estrogen Receptor Agonist

Estrogen Receptor Agonist Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	7.5%
Base Year Market Size (2023)	USD 4.3 Billion
Forecast Year Market Size (2036)	USD 11.01 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of estrogen receptor agonist is evaluated at USD 4.59 Billion.

The estrogen receptor agonist market size was valued at USD 4.3 Billion in 2023 and is expected to exceed USD 11.01 Billion by the end of 2036, expanding at over 7.5% CAGR during the forecast period i.e., between 2024-2036. The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

Asia Pacific industry is set to have the highest growth by 2036, backed by growing geriatric population in this region.

AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, Merck KGaA, Vivesto AB, Oncternal Therapeutics, Pfizer Inc., Tocris Bioscience, Tokyo Chemical Industry Co., Ltd

Estrogen Receptor Agonist Market Trends